MSB 3.21% $1.13 mesoblast limited

The competition to Remestemcel-L in COVID-19, page-160

  1. 240 Posts.
    lightbulb Created with Sketch. 123
    Interestingly DemiurgeTech (@DemiurfgeTech on Twitter), the AI based prediction company which claims a better than 80% success rate in predicting the outcomes of clinical trials, predicts a fail for Moderna's vaccine clinical trial:





    Demiurge AI-based #covid19#vaccine#clinicaltrial outcome predictions put to the public test (120_2020): FAILURE for #mRNA-1273 / NCT04470427 / $MRNA

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.